

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new pages 1-19 in the above-captioned application. A computer-readable copy (CRF copy) of the Sequence Listing accompanies this response.

**AMENDMENTS**

In the Claims

in p/c Amdt A

Please replace the paragraph beginning at page 2, line 9, with the following rewritten paragraph:

33. The antibodies of claim 32 wherein said peptide is human brain natriuretic peptide of the formula:

$R^1\text{-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Gly-Leu-Gly-Cys-R}^2$  (SEQ ID

NO: 5)

wherein  $R^1$  is selected from the group consisting of:

(H);

Gly-;

Ser-Gly-;

Gly-Ser-Gly-;

Gln-Gly-Ser-Gly-;

Val-Gln-Gly-Ser-Gly-;

Met-Val-Gln-Gly-Ser-Gly-;

Lys-Met-Val-Gln-Gly-Ser-Gly-;

Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-;

Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-; and

$R^3\text{-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-}$  (SEQ ID Nos: 6-11)

wherein  $R^3$  is the 101 amino acid sequence shown for human BNP in Figure 8 at positions numbered 1-99 immediately upstream of the Ser residue to which  $R^3$  is bound, or a C-terminal portion thereof; and-

*in pre amdt A*

Please replace the paragraph beginning at page 3, line 1, with the following rewritten paragraph:

~~- R<sup>2</sup> is OH, NH<sub>2</sub> or NR<sub>2</sub> wherein each R is independently H or lower alkyl (1-4C); or R<sup>2</sup> is selected from the group consisting of:~~

Lys;  
Lys-Val;  
Lys-Val-Leu;  
Lys-Val-Leu-Arg;  
Lys-Val-Leu-Arg-Arg; and  
Lys-Val-Leu-Arg-Arg-His, or  
the C-terminal amides thereof. (SEQ ID NOS: 12-14)

~~Please replace the paragraph beginning at page 3, line 11, with the following rewritten paragraph:~~

~~34. The antibodies of claim 33 wherein the peptide is of the formula:~~

~~Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His,~~  
~~or a C-terminal amide thereof. (SEQ ID NO: 49)~~

~~Please replace the paragraph beginning at page 3, line 22, with the following rewritten paragraph:~~

~~37. The antibodies of claim 32 wherein said peptide is canine natriuretic peptide of the formula:~~

~~R<sup>1</sup>-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R<sup>2</sup> (SEQ ID NO: 5)~~  
wherein R<sup>1</sup> is selected from the group consisting of:

~~(H);~~

~~Gly-;~~

~~Ser-Gly-;~~

~~Lys-Ser-Gly-;~~

Serial No. 09/902,517  
Docket No. 219002025213

3<sup>rd</sup> cont'd

His-Lys-Ser-Gly-;  
Met-His-Lys-Ser-Gly-;  
Met-Met-His-Lys-Ser-Gly-;  
Lys-Met-Met-His-Lys-Ser-Gly-;  
Pro-Lys-Met-Met-His-Lys-Ser-Gly-; and  
**R<sup>3</sup>-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-; (SEQ ID NOS: 6-11)**

wherein R<sup>3</sup> is the 100 amino acid sequence of the dog prepro sequence upstream of the Ser residue to which R<sup>3</sup> is bound shown in Figure 8 herein or a C-terminal portion thereof;

R<sup>2</sup> is OH, NH<sub>2</sub>, or NR<sub>2</sub> wherein each R is independently H or lower alkyl (1-4C) or R<sup>2</sup> is

Asn;

Asn-Val;

Asn-Val-Leu;

Asn-Val-Leu-Arg;

Asn-Val-Leu-Arg-Lys; or

Asn-Val-Leu-Arg-Lys-Tyr;

or a C-terminal amide thereof. (SEQ ID NOS: 12-14)]

*in pre amdt A*  
Please replace the paragraph beginning at page 4, line 16, with the following rewritten paragraph:

~~38. The antibodies of claim 37 wherein said canine natriuretic peptide is  
Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-  
Leu-Ser-Gly-Leu-Gly-Cys-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Asn-Val-Leu-Arg-Lys-  
Tyr;  
or a C-terminal amide thereof. (SEQ ID NO: 50)]~~

In the Specification:

Please replace the paragraph beginning at page 3, line 19, with the following rewritten paragraph:

~~One of these factors from porcine brain has been isolated and sequenced by Sudoh, P.,  
Nature (1988) 332:78-81. It is a 26-amino acid peptide synthesized in porcine brain and atrial tissue  
at about 1/100 of the concentration of analyzed atrial natriuretic peptide (ANP) activity. The~~